AYTU BioPharma (AYTU)

• Market cap: $21.2M
• 1 day: 2.61%
• 5 days: 3.51%
• 1 month: 4.89%
• 3 months: 21.03%
• 6 months: 85.83%
• Year to date: 38.82%
• 1 year: -6.35%
• 5 years: -99.01%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Employees: 102

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

199% more capital invested

Capital invested by funds: $2.49M [Q1] → $7.45M (+$4.96M) [Q2]

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

7.64% more ownership

Funds ownership: 30.42% [Q1] → 38.06% (+7.64%) [Q2]

3% more funds holding

Funds holding: 31 [Q1] → 32 (+1) [Q2]

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8
• Avg. target: $10
• High target: $12

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Lake Street Thomas Flaten	$8	Buy Initiated	1 Jul 2025
Ascendiant Capital Edward Woo	$12	Buy Initiated	30 Jun 2025